Novel anti-malarial combinations and their toxicity.
Artemisinin combination therapy for the treatment of uncomplicated malaria includes artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, artesunate plus sulfadoxine-pyrimethamine and dihydroartemisinin plus piperaquine. These drugs are safe and efficacious at present. The emergence of artemisinin resistant parasites in SE Asia means that there is a need to optimise drug dosing and investigate novel therapies to maintain the impressive reduction in malaria mortality which has been seen in the past decade.
Nuffield Department of Medicine, University of Oxford, Rm7400, Level 7 The John Radcliffe, Headington, Oxford, OX39DU, UK.
Brian
B
Angus
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D015394:Molecular Structure; D060735:Pharmacovigilance; D010963:Plasmodium falciparum / Q000187:drug effects*
D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin